SCHEMBL239384

SCHEMBL239384

Cc1cc2ncc3cc(-c4cccs4)c(Cl)nc3n2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 3/20 0.39
HPGD P15428 3/20 0.39
RAB9A P51151 2/20 0.39
TP53 P04637 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
FYN P06241 6/20 0.36
PDE10A Q9Y233 2/20 0.35
HSD17B10 Q99714 2/20 0.35
POLB P06746 2/20 0.35
BTK Q06187 1/20 0.35
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238212 0.88 KDM4E (0.37) ALDH1A1KDM4EL3MBTL1NPC1HPGD
SCHEMBL239555 0.86 CYP11B1 (0.36) ALDH1A1KDM4EL3MBTL1NPC1RAB9A
SCHEMBL239178 0.82 ALDH1A1 (0.37) ALDH1A1KDM4EL3MBTL1HPGDCYP11B1
SCHEMBL2755267 0.81 PIM1 (0.41) ALDH1A1KDM4EL3MBTL1NPC1HPGD
SCHEMBL235881 0.81 RAB9A (0.48) ALDH1A1KDM4EL3MBTL1NPC1HPGD
SCHEMBL238754 0.80 NPC1 (0.41) ALDH1A1KDM4ENPC1HPGDRAB9A
SCHEMBL238671 0.80 NPC1 (0.41) ALDH1A1KDM4ENPC1HPGDRAB9A
SCHEMBL238454 0.80 HTT (0.49) L3MBTL1NPC1HPGDRAB9ATP53
SCHEMBL239038 0.79 RAB9A (0.42) NPC1HPGDRAB9ATP53MEN1
SCHEMBL238571 0.78 NPC1 (0.61) ALDH1A1KDM4EL3MBTL1NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 ALDH1A1 3980/4885KDM4E 2166/4885L3MBTL1 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.